Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15347788 | 0.99 | BDKRB1 (0.37) | BDKRB1POLBGAATSHRKDM4E | |
| SCHEMBL4472823 | 0.90 | KDM4E (0.39) | BDKRB1POLBGAATSHRKDM4E | |
| SCHEMBL4461535 | 0.88 | FABP4 (0.43) | POLBKDM4E | |
| SCHEMBL4484350 | 0.86 | TDP1 (0.36) | POLBGAATSHRKDM4ETDP1 | |
| SCHEMBL4781829 | 0.85 | BDKRB1 (0.36) | BDKRB1KDM4ETDP1 | |
| SCHEMBL10008677 | 0.85 | FABP4 (0.48) | BDKRB1POLBGAATSHRTDP1 | |
| SCHEMBL492918 | 0.84 | F2 (0.39) | TSHR | |
| SCHEMBL5125870 | 0.84 | HTT (0.43) | POLBGAATSHRTDP1HPGD | |
| SCHEMBL4472447 | 0.84 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL3998878 | 0.81 | FFAR4 (0.33) | BDKRB1TSHRKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130289049-A1 | ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-METHYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL] ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTORANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2601181-A1 | ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-METHYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8207335-B2 | Process for making certain compounds having B1 antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| WO-2012017027-A1 | ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-METHYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL] ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| EP-2396308-A1 | NEW PRODUCTION METHOD | Boehringer Ingelheim International GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2240458-B1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110046106-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2240458-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | Boehringer Ingelheim International GmbH (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100210842-A1 | PROCESS FOR PREPARING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| WO-2009098051-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | WO | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| WO-2008024692-A1 | N-OXIDE ARYL SULFONES AND SULFOXIDES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007140383-A2 | SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | BDKRB1 11/4885POLB 1378/4885GAA 1470/4885 |
| US-20130289049-A1 | ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-METHYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL] ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTORANTAGONISTS | BDKRB1, BDKRB2, AGTR1 | BDKRB1 1/4885POLB 1885/4885GAA 2512/4885 |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885POLB 1783/4885GAA 215/4885 |
| US-20100210842-A1 | PROCESS FOR PREPARING | CYP11B1, CYP11B2, CYP2F1 | BDKRB1 226/4885POLB 429/4885GAA 1235/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | BDKRB1 1/4885POLB 4295/4885GAA 4502/4885 |
| US-20110046106-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | SULT2A1, SULT1A1, ARSA | BDKRB1 178/4885POLB 4021/4885GAA 2548/4885 |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | BDKRB1 1/4885POLB 3990/4885GAA 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.